Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

329results about "Fluorine compound active ingredients" patented technology

Porous ceramic composite bone grafts

The invention relates to porous ceramic composites incorporating biodegradable polymers for use as a bone substitute in the fields of orthopaedics and dentistry or as a scaffold for tissue engineering applications. The porous ceramic composite implant for connective tissue replacement comprises a porous ceramic matrix having a biodegradable polymer provided on internal and external surfaces of the ceramic matrix. The biodegradable polymer allows for the passage and / or delivery of a variety of agents throughout the porous ceramic matrix and improves mechanical properties of the implant in vivo.
Owner:WARSAW ORTHOPEDIC INC

Microencapsulated compositions and methods for tissue mineralization

The present invention is directed to compositions, products and methods useful for bone and tooth mineralization. The compositions comprise polymer microcapsules containing aqueous salt solutions. The shells of the microcapsules can be semi-permeable or impermeable. Solutions of calcium, fluoride and phosphate salts are particularly useful in the compositions of the invention. The microcapsules are preferably prepared by surfactant free inverse emulsion interfacial polymerization. Bone products include cements, scaffolds and bioactive glass. Dental products include pastes, gels, rinses and many other dental materials.
Owner:PREMIER DENTAL PRODS

Modified alpha-MSH peptides and derivatives thereof

Novel peptides with antimicrobial activity are disclosed. The novel peptides are octomeric peptides modified from alpha-MSH. The modified alpha-MSH antimicrobial peptides disclosed herein may have enhanced activity against microbes over alpha-MSH due to modifications in peptide sequence and chirality of amino acids. Due an identified mechanism of action for antimicrobial activity in which cAMP accumulates in the microbial cell, it may be that microbes will not generate resistance to these modified alpha-MSH antimicrobial peptides.
Owner:ZENGEN

Gradient coating for biomedical applications

The present invention provides a coating comprising a bioactive material and an antimicrobial agent, wherein the concentration of said antimicrobial agent varies throughout the thickness of the coating.
Owner:SMITH & NEPHEW INC

N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them

ActiveUS20060247209A1Favorable therapeutic indexEfficacy can not be compromisedAntibacterial agentsBiocideDisinfectantAnti infectives
The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.
Owner:NOVABAY PHARM INC

Prevention of loss and restoration of bone mass by certain prostaglandin agonists

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis.
Owner:PFIZER INC +1

Cyclic peptide compositions for treatment of sexual dysfunction

A cyclic peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, m and p are as defined. Further provided are compositions for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Routes of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.
Owner:PALATIN TECH INC

Fluoride varnish compositions including an organo phosphoric acid adhesion promoting agent

Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to provide biologically available fluoride ions to the tooth tissue being treated. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and / or other factors.
Owner:ULTRADENT PROD INC

Multiple agent therapy for sexual dysfunction

Multiple agent therapy for treatment of sexual dysfunction, including male erectile dysfunction, with sequential administration a type V phosphodiesterase inhibitor (PDE-5), such as sildenafil, preferably wherein the PDE-5 inhibitor is administered by oral dose means, and a melanocortin 3 and / or 4 receptor agonist, such as Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH (PT-141) preferably wherein the PT-141 is formulated for and administered by intranasal means, and further preferably wherein the PDE-5 inhibitor is administered prior to PT-141.
Owner:PALATIN TECH INC

Novel chemical entities and methods for their use in treatment of metabolic disorders

Methods and composition for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compounds to said patient at a level to produce an improvement in cognitive ability.
Owner:ACCERA INC

Composition containing nano-crystalline apatite

This invention describes compositions containing nano-crystalline apatite useful as bone—or preferably as tooth restorative materials. The materials produced, using the composition have improved properties in the areas of esthetics, hardness, translucency, surface polishability, strength and the capability to release and to take ions up in respect of a biological environment.
Owner:S & C POLYMER SILICON & COMPOSITE SPEZIALITATION +1

Therapeutically active alpha msh analogues

The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native α-MSH peptide. The α-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to α-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.
Owner:ABBVIE INC

Bioactive glass composition, its applications and respective preparation methods

ActiveUS20140193499A1Easy to sinterHigh in vitro biomineralization rateBiocideCosmetic preparationsFlexural strengthChemistry
The present invention relates to development of bioactive glass / glass-ceramic composition that are able to promote a fast deposition layer of carbonated hydroxyapatite upon immersion in simulated body fluid (SBF) for time periods as short as one hour. Such composition might include fluorides, and a variety of oxides (or their precursor compounds), such as Na2O—Ag2O—SrO—CaO—MgO—ZnO—P2O5—SiO2—Bi2O3—B2O3—CaF2, be prepared by the melt route or by the sol-gel process, with the specific composition and the preparation route selected according to the intended functionalities, which can present controlled biodegradation rate and bactericidal activity. The powders derived from glass melts purred in cold water (frits) may completely densify by sintering at temperatures up to 800° C. without devitrification, resulting in bioglass compacts with high flexural strength (˜85 MPa). The bioactive glass powders prepared by sol-gel densify at lower temperatures due to their higher specific surface area and reactivity.
Owner:REG4LIFE REGENERATION TECH

Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate

The present invention provides novel biomaterials comprising one or more of Mg, Zn and F ions in a carbonate-containing biphasic calcium phosphate (BCP) system. The biomaterial may contain Mg, Zn, F, Mg and Zn, Mg and F, Zn and F, or Mg, Zn and F. The biomaterial may be substantially similar in composition to bone mineral (a carbonate apatite). The biomaterial may feature slow release of Mg, Zn, F, Ca, and P ions. The biphasic calcium phosphate, BCP, may be a mixture of unsubstituted hydroxyapatite (HA) and unsubstituted .-TCP, Ca3(PO4)2. BCP of varying HA / .-TCP ratios may be produced by sintering calcium-deficient apatite, for instance having a Ca / P<1.5, 1.6, 1.67, 1.75 or 1.8 that has been prepared either by a precipitation or by a hydrolysis method or by a solid-state reaction. The amount of each component (by weight %) present in the biomaterials may be as follows: Mg 0.5 to 12 wt %, Zn 1 to 12 wt %, F 0.1 to 4 wt %, calcium 20 to 40 wt %, phosphate 10 to 20 wt %, and carbonate (CO3) 1 to 20 wt %. The biomaterial may further comprise one or more other ion such as strontium, manganese, copper, boron or silicate, or one or more other organic moiety such as a protein, a peptide, or a nutraceutical which may provide antioxidant, anti-bacterial or anti-inflammatory properties. The invention also provides methods of inhibiting bone resorption, methods of treating osteoporosis or delaying the onset of osteoporosis, methods of treating a bone fracture, and methods of inhibiting osteoclast activity. Further, the invention provides methods of treating or reversing bone deficiencies such as bone loss, similar to osteoporosis, caused all or in part by a mineral deficient diet, a disease such as cancer or osteopenia, a treatment such as steroid therapy or radiation therapy, or a physical condition such as immobilization.
Owner:NEW YORK UNIV

Use of phosphatases to treat neuroblastomas and medulloblastomas

Disclosed herein are methods of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a phosphatase ligand in an amount effective to treat the subject. Also disclosed herein are method of treating neuroblastomas and medulloblastomas in a subject comprising administering to the subject a histone deacteylase ligand in an amount effective to treat the subject.
Owner:LIXTE BIOTECH +1

Composition for caries prevention

InactiveUS20050089481A1Excellent composition for preventionInhibition is effectiveCosmetic preparationsImpression capsCementum cariesPhosphopeptide
To obtain a composition for caries prevention, which has effects for efficiently suppressing demineralization and promoting remineralization and stability in keeping for a long time, 0.01 to 10% by weight of sodium carboxymethylcellulose having the etherification degree of 0.7 to 1.0 is used in a composition blended with a casein phosphopeptide-amorphous calcium phosphate complex (CPP-ACP) and / or a casein phosphopeptide-amorphous calcium fluoride phosphate complex (CPP-ACFP), a sodium carboxymethylcellulose, a viscosity regulator and water.
Owner:GC CORP

Compositions to control oral microbial oxidation-reduction (Eh) levels

The present invention relates to an oral composition containing a zinc compound containing free available zinc ion and at least one stabilized or stable Eh raising compound distributed in an oral vehicle. The present invention further relates to a method of inhibiting the formation of sulfur containing anions and preventing a reduction in the Eh of the oral cavity. A method of reducing oral malodor and gingivitis and periodontitis is also provided by this invention.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK

Osteogenic and anti-adipogenic oxysterols

The present invention discloses osteogenic and anti-adipogenic oxysterols. Agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation are disclosed. Exemplary agents include oxysterols alone or in synergistic combinations, as well as hedgehog or Wnt signaling activators. The synergistic effects of oxysterols and bone morphogenic proteins are also disclosed.
Owner:RGT UNIV OF CALIFORNIA

Agents and Methods for Osteogenic Oxysterols Inhibition of Oxidative Stress on Osteogenic Cellular Differentiation

The present invention discloses oxygenic oxygenic oxysterols. Also disclosed, agents and methods for protecting, blocking or rescuing marrow stromal cells from the inhibitory effects of oxidative stress on their osteoblastic cellular differentiation. Exemplary agents include oxysterols, rhBMP2, alone or in combination which are demonstrated to specifically combat oxidative stress caused by inflammatory oxidized lipids, such as xanthine / xanthine oxidase and minimally oxidized LDL. The synergistic effects of oxysterols and bone morphogenic proteins are disclosed.
Owner:RGT UNIV OF CALIFORNIA

Dentin mineralizing agent and method for production thereof

InactiveUS20120027829A1Impart caries resistanceTreatmentCosmetic preparationsImpression capsO-Phosphoric AcidMedicine
A dentin mineralizing agent comprising tetracalcium phosphate particles (A) and an alkali metal salt of phosphoric acid (B), wherein the dentin mineralizing agent contains the tetracalcium phosphate particles (A) in an amount of 1 to 80 parts by weight relative to 100 parts by weight of the whole amount of the dentin mineralizing agent, and the blended amount of the alkali metal salt of phosphoric acid (B) relative to 100 parts by weight of the tetracalcium phosphate particles (A) is 1 to 100 parts by weight. Thus is provided a dentin mineralizing agent by which a dense HAp is formed on a dentin surface and HAp is deposited to a deep portion of a dentinal tubule, so that it can close the dentinal tubule.
Owner:KURARAY NORITAKE DENTAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products